NCP Flanders
choose your programme
Horizon Europe

Horizon Europe is the main Research and Innovation Funding Programme of the European Commission.

Horizon 2020

Horizon 2020 is the previous Funding Programme. There are no longer calls, but projects can run until 2024.

Digital Europe

Digital Europe is a Funding Programme focused on bringing digital technology to businesses, citizens and administrations.

Other EU Funding

There are many other relevant EU funding programmes, managed by several agencies and directorates.

News and Updates

Find out what's happening in the area of Horizon Europe, Digital Europe and Horizon 2020

Horizon 2020 & Horizon Europe final and interim evaluations

Published on | 1 year ago

Programmes Horizon Europe   Horizon 2020  

A final evaluation of the Horizon 2020 programme (2014-2020) and an interim evaluation of the Horizon Europe programme (2021-2023) are announced and include stakeholder consultations.  

The Horizon 2020 final evaluation runs from the second quarter of 2022 up to the fourth quarter of 2023. It will analyse the design and implementation, results and impacts of the programme from 2014 to 2020 and covers all Horizon 2020 instruments. The Horizon Europe interim evaluation runs from the fourth quarter of 2022 up to the third quarter of 2024. It will analyse the programme’s design, implementation and first results and will cover all Horizon Europe instruments.  

For both evaluations the following stakeholder consultations are planned:

  • A 12-week public consultation to be published in English, French and German on the Have Your Say website in the fourth quarter of 2022. Responses may be submitted in any official EU language. Shortly after it has closed, a factual summary report will be published on the same website, along with the respondents’ replies. The same consultation will also cover Horizon Europe (interim evaluation and preparations for the 2025-27 Horizon Europe strategic plan).
  • Targeted consultations (e.g. workshops, interviews) for applicants, participants, national and regional authorities and business representatives. These have already started as part of external evaluation studies supporting this evaluation.
  • An online event, planned in the second quarter of 2023 to harvest more stakeholder views.

The consultations are targeted at main stakeholders identified which include researchers, business, academia, non-governmental organisations, public authorities, and EU-wide ‘umbrella’ organisations.

These evaluations will help the European Commission with implementation of current EU research and innovation measures and with the design of future measures. It also fulfils the Commission’s legal obligation to explain how it has spent public funds.

More information on these initiatives can be found on the “Have your say” webpage of the European Commission. For Horizon 2020 final evaluation here and for Horizon Europe interim evaluation here 

myOVERVIEW
- sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon 2020 & Horizon Europe.

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1287 articles available search in articles 

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.